到凝乳
发表于 2025-3-21 19:00:10
书目名称Biomarkers in Inflammatory Bowel Diseases影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0187813<br><br> <br><br>书目名称Biomarkers in Inflammatory Bowel Diseases读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0187813<br><br> <br><br>
ABHOR
发表于 2025-3-21 23:28:09
http://reply.papertrans.cn/19/1879/187813/187813_2.png
不能约
发表于 2025-3-22 01:09:05
Clinical Trial Design to Facilitate Biomarker Discoveryent would be valuable. Data and materials collected in clinical trials are a valuable source for identification of predictive biomarkers or development of pharmacokinetic models. By using a dashboard system with an incorporated pharmacokinetic model, the exact medication dose a patient should receiv
有危险
发表于 2025-3-22 04:39:53
Luminal Crohn’s Diseasertreating those with symptoms unrelated to their CD..Therefore, in addition to assessing clinical symptoms, there is a need to incorporate more objective markers of disease activity into the management of CD. In the pursuit of providing such information, a number of tools have been assessed in their
闲荡
发表于 2025-3-22 12:01:26
http://reply.papertrans.cn/19/1879/187813/187813_5.png
钱财
发表于 2025-3-22 16:48:03
http://reply.papertrans.cn/19/1879/187813/187813_6.png
兽群
发表于 2025-3-22 20:58:46
Refractory Proctitisst of the other potential topical agents is limited to open-labelled studies alone and thus requires a great deal more investigation. The use of systemic, immunomodulatory and biological agents in proctitis is the same as for left-sided and extensive UC. Therapy has undoubtedly improved over recent
鼓掌
发表于 2025-3-23 00:53:25
The Role of Biomarkers in the Ileal Anal Pouchlp guide clinicians. These biomarkers can help predict those that will develop pouchitis and may therefore be useful as a surveillance strategy to enable prompt treatment before symptoms of pouchitis develop..Despite their potential, no biomarker has been validated for its use in pouchitis, and the
Cervical-Spine
发表于 2025-3-23 04:24:13
http://reply.papertrans.cn/19/1879/187813/187813_9.png
Soliloquy
发表于 2025-3-23 07:03:33
https://doi.org/10.1007/978-3-642-96306-3rgical intervention in CD, compared with proximal disease extension, hospitalization, and colectomy in UC. Age at onset, disease phenotype characteristics (early disease course, behavior and localization/disease extension), smoking status, and accelerated treatment algorithms in early disease were r